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Abstract
Background:  Invasion and metastasis is a complex process governed by the interaction of genetically
altered tumor cells and the immunological and inflammatory host reponse. Specific T-cells directed against
tumor cells and the nonspecific inflammatory reaction due to tissue damage, cooperate against invasive
tumor cells in order to prevent recurrences. Data concerning involvement of individual cell types are
readily available but little is known about the coordinate interactions between both forms of immune
response.
Patients and methods:  The presence of inflammatory infiltrate and eosinophils was determined in 1530
patients with rectal adenocarcinoma from a multicenter trial. We selected 160 patients to analyze this
inflammatory infiltrate in more detail using immunohistochemistry. The association with the development
of local and distant relapses was determined using univariate and multivariate log rank testing.
Results:  Patients with an extensive inflammatory infiltrate around the tumor had lower recurrence rates
(3.4% versus 6.9%, p = 0.03), showing the importance of host response against tumor cells. In particular,
peritumoral mast cells prevent local and distant recurrence (44% versus 15%, p = 0.007 and 86% versus
21%, p < 0.0001, respectively), with improved survival as a consequence . The presence of intratumoral
T-cells had independent prognostic value for the occurrence of distant metastases (32% versus 76%, p <
0.0001).
Conclusions:  We showed that next to properties of tumor cells, the amount and type of inflammation
is also relevant in the control of rectal cancer. Knowledge of the factors involved may lead to new
approaches in the management of rectal cancer.
Background
The infiltration of inflammatory cells in cancer tissues is
considered an important aspect of the host response in
cancer. The altered phenotype of cancer cells might
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evoke a specific immune response and influx of lym-
phocytes in the tumor area, while the disorganization
and damage of the surrounding tissue leads to a more
general inflammatory response, which is mainly present
around the tumor. The inflammatory response can have
dual effects in the progression of cancer. On one hand in-
flammatory cells are a prognostic good sign, probably by
maintaining control due to elimination of tumor cells
[1,2], while on the other hand production of cytokines
and growth factors can provide a growth stimulating mi-
croenvironment for tumor cells [3,4,5,6].
Table 1: Categorical arrangements for the different cell types in 160 rectal cancer patients.
cell type (antibody) intratumoral peritumoral
cells / mm2 % of patients cells / mm2 % of patients
eosinophils (EG-2) n = 159 n = 140
none/few 0-10 29 0-50 31
moderate 11-50 50 51 - 200 43
many > 50 21 > 200 26
neutrophils (elastase) n = 160 n = 152
none/few 0-5 21 0 - 75 24
moderate 6 - 50 54
many > 50 25 > 75 76
mast cells (tryptase) n= 160 n = 151
none/few 0 -5 19 0-30 25
moderate 6 -50 52 31 -100 59
many > 50 29 > 100 16
macrophages (CD68) n = 159
none/few 0-50 28
moderate 51 -150 50
many > 150 22
NK cells (CD56) n = 159 n = 136
none 0 33 0 43
moderate/many > 0 67 > 0 57
T cells (CD3) n = 158 n = 157
none/few 0-55 27 0-300 20
moderate 56-105 36 301 - 500 51
many >105 37 > 500 29
CD4+ cells n = 156 n = 130
none/few 0-30 43 0-20 24
moderate 31 -65 26 21 -110 50
many >65 31 > 110 26
CD8+ cells n = 159 n = 122
none/few 0-15 26 0-135 77
moderate 16-75 47
many >75 27 > 135 23
Peritumoral infiltrate could not be reliably determined in all patients, because of the absence of invasive front in several tumor samples.BMC Cancer (2001) 1:7 http://www.biomedcentral.com/1471-2407/1/7
Although in most solid cancer types the emphasis is
placed on the presence of T lymphocytes as a specific
anti-cancer reaction [7,8,9], there is a role for the non-
specific inflammation reaction as well, since the pres-
ence of NK cells [10,11], macrophages [12,13,14], mast
cells [15,16,17] and neutrophilic and eosinophilic granu-
locytes [16,17,18,19] have prognostic value in various sol-
id cancer types. The importance of the presence of these
different cells is usually analyzed for one cell type. How-
ever, the complex interactions between the specific and
the general immunologic reaction require an integrated
study of the different cell types.
In rectal cancer, the importance of the inflammatory in-
filtrate is recognized and used in the staging of tumors by
the Jass' classification [20]. This classification was ini-
tially developed for the prediction of survival, but is also
useful in predicting recurrence of disease [21]. One of the
most important problems in rectal cancer is local recur-
rence [22]. Local recurrence causes profound morbidity
and is a major cause of rectal cancer related death. In the
Netherlands a randomized multicenter trial was started
to evaluate the effects of preoperative radiotherapy and
total mesorectal excision (TME) on the local recurrence
rate in rectal cancer [23]. In this trial radiotherapy, sur-
gery and pathology are standardized, to provide optimal
conditions for studying local recurrence.
The purpose of the current study was to evaluate the
prognostic potential of various inflammatory cell types
present in and around rectal carcinoma and to determine
their significance for the prognosis in relation to TNM
stage. With these data we developed a model integrating




Patients were obtained from the TME trial, a large mul-
ticenter trial in the Netherlands, in which 1530 patients
were included from January 1996 till December 1999
[23]. In this randomized trial the additional value of pr-
eoperative radiotherapy (5 ×  5 Gy) is studied when TME
(Total Mesorectal Excision) surgery is applied. Radio-
therapeutical, surgical and pathological procedures are
standardized and quality controlled [24].
For the analysis of the prognostic value of the amount of
inflammatory infiltrate as well as eosinophilic granulo-
cytes, we analyzed the data from all eligible patients in
this trial (n = 1416). We selected 160 patients for the
analysis of the cellular composition of the inflammatory
infiltrate in relation to prognosis. Since local recurrence
rates are very low when TME surgery is applied, an artif-
ical selection was made to be able to study the role of in-
flammatory cells in both local and distant control. 40
stage II patients and 40 stage III patients without distant
metastases or local recurrence (after a median follow-up
of 21 months), 40 with distant metastases without local
recurrence and 40 patients with local recurrence without
metastases were selected. This selection of patients im-
plies that survival percentages in this study cannot be ex-
trapolated towards the general patient population,
however, we can compare the effects of the different cell
types on patients' prognosis. Patients were selected from
both randomization groups. Analyses were performed
using stratification for the randomization arms to ex-
clude a possible therapy related effect.
Follow up of all patients in the trial for the endpoints was
conducted according to the trial protocol for at least 36
months. Median follow up at the moment of writing was
19.6 months. Median follow up of the selection of 160 pa-
Table 2: Results of univariate log rank analyses for the risk on local recurrence, the risk on distant metastases and the survival for the 
presence  of inflammatory infiltrate and eosinophilic granuloytes.
inflammatory infiltrate eosinophilic granulocytes
none/few extensive P none/ few moderate extensive P
local recurrence rate 6.9% 3.4% 0.03 7.4% 4.8% 2.8% 0.10
(2 year)
distant metastases 23.8% 8.2% <0.0001 23.8% 16.8% 16.1% 0.03
rate (2 year)
cumulative survival 79.1% 92.0% <0.0001 79.0% 84.1% 86.9% 0.007
(2 year)
Median follow-up is 19.6 months, n = 1416.BMC Cancer (2001) 1:7 http://www.biomedcentral.com/1471-2407/1/7
tients is 35.4 months. Distant and local recurrences were
checked by a radiation oncologist (CAMM) by radiologi-
cal and/or histological confirmation.
Tissue preparation
Tissue samples of the primary tumors were fixed in 4%
(v/v) phosphate buffered formalin, dehydrated and em-
bedded in paraffin. Tissue sections of 4 µm were cut,
mounted onto glass slides pretreated with 2% 3-amino-
propyltriethoxysilane (Sigma) and dried overnight. Seri-
al sections were stained with hematoxylin and eosin or
processed for immunohistochemistry.
Evaluation of peritumoral inflammatory infiltrate and 
eosinophilic granulocytes
Routine hematoxylin and eosin-stained histopathologi-
cal sections were used to determine the infiltration of
lymphocytes and eosinophils at the advancing border of
the tumors for all patients by pathologists of the Pathol-
ogy Review Committee (PRC). Tumor slides of all pa-
tients in the trial were send to the PRC, who examined
them using the following categories for inflammatory in-
filtrate: none/few and extensive, as described by Jass et
al. [20]. Eosinophilic granulocytes were scored as none/
few, moderate and extensive.
Immunohistochemistry
Determination of the various inflammatory cells was as-
sessed by immunohistochemical investigation with the
following antibodies: anti-CD3 (Anti Human T Cell, 1:
1600, Dako A/S Glostrup, Denmark), anti-CD4 (1: 400,
Novo Castra, Newcastle, UK), anti-CD8 (1: 3200, Novo
Castra, Newcastle, UK), anti-CD56 (Anti-N-CAM-16, 1:
3000, Becton Dickinson, San Jose CA, USA), anti-CD68
(Anti Human Macrophage, 1: 6400,Dako A/S, Glostrup,
Denmark), AA-1 (Anti Human Mast Cell Tryptase, 1:
3200, Dako A/S, Glostrup, Denmark), elastase (Anti-
Human Neutrophil Elastase, 1: 800, Dako A/S, Glostrup,
Denmark), EG-2 (Anti-Human ECP/EPX, 1: 1000, Phar-
macia Upjohn, Uppsala, Sweden). In brief, sections were
deparaffinized in xylene, and rehydrated. Endogenous
peroxidase was blocked with 0.3% hydrogen peroxide in
methanol for 20 minutes. Antigen retrieval was per-
formed using 0.01 M citrate buffer (anti-CD3, Ki-67), 1
mM EDTA (anti-CD8, anti-CD56, anti-CD4), and 0.1%
Trypsine (anti-CD68), respectively. Subsequently, sec-
tions were preincubated with 1% bovine serum albumin.
After overnight incubation with the primary antibody,
the secondary biotin-conjugated antibody and a tertiary
complex of streptavidin-avidin-biotin conjugated to 3-
amino-9-ethyl-carbazole were applied. Finally, the sec-
tions were counterstained with Mayer's hematoxylin. In-
cubation with phosphate-buffered saline instead of the
primary antibody served as a negative control.
Scoring methods and categories
The 'running mean' method was used to determine the
minimum number of high power fields (HPFs) to be
scored for the result to be reliable. Two independent in-
vestigators (IDN and AAMS) performed this determina-
tion on three different tumors. This was done by
calculating stepwise the mean number of inflammatory
cells for the total of HPFs until the difference between
the successive means became negligibly small. The
number of HPFs varied between 11 and 15 for the various
cell types; therefor, it was decided to count 15 HPFs (2.1
mm2) for every cell type.
The scoring was performed within the tumor (intratu-
moral infiltrating cells, present in the stroma of the tu-
mor), as well as separately along the invasive border of
the tumor in the surrounding tissue (peritumoral infil-
trating cells), by one investigator. Necrotic areas were
avoided.
After analysis of the distribution of the numbers of in-
flammatory infiltrating cells, the counts were divided
into two or three categories: none/few, (moderate) and
many, based on the distribution of the numbers of cells
in the study population (see table 1). Because of the high
Table 3: Results of the multivariate Cox regression analysis for the risk on local recurrence, distant metastases and survival for the pres-
ence of inflammatory infiltrate and TNM classification.
local recurrence distant metastases 2 year survival
R R9 5 % C IR R9 5 % C IR R9 5 % C I
TNM I/II 1.0 1.0 1.0
TNM III/IV 4.8 2.7-8.8 2.8 2.2-3.7 5.8 4.1-8.3
none/few inflammatory cells 1.0 1.0 1.0
extensive inflammatory infiltrate 1.7 0.7-4.3 2.6 1.5-4.6 2.4 1.2-4.5
Median follow up is 19.6 months, n = 1416. RR: relative risk, Cl: confidence intervalBMC Cancer (2001) 1:7 http://www.biomedcentral.com/1471-2407/1/7
numbers of peritumoral macrophages, the peritumoral
macrophage infiltrate (CD68) was scored semiquantita-
tively by three independent investigators (IDN, AAMS,
and JHJMvK), using three categories: none/few, moder-
ate and extensive. In general, the agreement of the three
investigators was good (82.5% agreement). In a few cas-
es with poor agreement, the cases were reviewed using a
multi-headed microscope and a score agreed after dis-
cussion.
Effects of radiotherapy
Since we observed differences in cell counts between
both randomization groups [Nagtegaal ID, Marijnen
CAM, Klein Kranenbarg E, Mulder-Stapel AA, Hermans
J, van de Velde CJH, van Krieken JHJM, et al., manu-
script submitted], we did a stratified analysis of all data
to minimize possible therapy related effects. Neutrophils
and T cells were decreased in the radiotherapy group.
There were no differences between both groups in num-
bers of mast cell, eosinophils, NK cells and macrophages.
Statistics
Differences between groups were obtained using the un-
paired Student's t-test. Relations between various pa-
rameters were analyzed using Χ 2 -methods, Mann
Whitney tests and bivariate Pearsons' correlation analy-
sis. Univariate survival analyses of time to local recur-
rence, distant metastasis or death were performed using
the Kaplan Meier method, with the time of surgery as the
entry date. Differences in observed survival between
groups were tested for statistical significance using log
ranks tests. The variables with a significant impact in the
univariate analysis (p < 0.05) were further examined us-
ing the Cox proportional hazards regression model; the
forward step-wise elimination method was used for this
multivariate analysis. Next, the prognostic value of the
selected cell types was analyzed additional to the TNM
classification and the presence of inflammatory infiltrate
using the enter method. Data were analyzed using the
SPSS software package (SPSS 9.0 for Windows, SPSS
Inc., Chicago, Illinois, USA).
All statistical analyses were stratified for randomization




The presence of extensive inflammatory infiltrate was as-
sociated with higher survival rates (p < 0.0001), lower
distant recurrence rates (p < 0.0001) and lower local re-
currence rates (p = 0.03) in the whole trial population (n
= 1416, median follow-up = 19.6 months) (table 2). Cox
regression revealed that the presence of inflammatory
infiltrate has additional value next to the TNM classifica-
tion with regards to the development of distant recur-
rence and survival (table 3).
Eosinophilic granulocytes
The presence of a high number of eosinophilic granulo-
cytes, as semiquantitatively scored by the PRC, was sig-
nificantly associated with higher survival rates (p =
0.007) and lower distant recurrence rates (p = 0.03) in
the whole trial population (table 2). Multivariate analysis
Table 4: Correlation coefficients for all cell types (Pearsons' analysis).
eo p (p) NF i (i) NF p (p) MC i (i) MC p (p) MΦ  i (i) NK i (i) NK p (p) CD3 i CD3 p CD4 i CD4 p CD8 i CD8 p
0.26* 0.37* 0.27* 0.17 0.17 Eo i (i)
0.21 0.24* 0.23* 0.18 Eo p (p)
0.63* 0.19 0.16 NF i
0.19 NF p (p)
0.29* 0.17 0.27* 0.19 0.25* 0.22* MC i (i)
0.16 0.19 0.22* 0.24* MC p
0.25* 0.30* 0.19 0.22 MΦ  i
0.20 NK i 
0.17 NK p
0.38* 0.36* 0.30* 0.16 CD3 i




Only the significant correlations are shown. The marked correlation coefficients (*) are significant with p values < 0.001, other correlations are sig-
nificant at a level of p < 0.05. (n = 160). Eo:eosinophilic granuloytes, NF:neutrophilic granulocutes, MC:mast cells, MΦ :macrophages, p: peritumoral, 
i: intratumoralBMC Cancer (2001) 1:7 http://www.biomedcentral.com/1471-2407/1/7
showed that the presence of eosinophilic granulocytes
did not have any additional prognostic value next to in-
flammatory infiltrate nor TNM classification.
Correlation of cell types mutual, with inflammatory infil-
trate
For all cell types there was a strong correlation between
their intratumoral and their peritumoral presence (table
4). The strongest relations were found between the num-
bers eosinophils and neutrophils, between macrophages
and NK cells, between mast cells and NK cells, and be-
tween T cells (CD3) and macrophages (figure 1). All cor-
relations are positive.
The amount of inflammatory infiltrate was significantly
correlated with the high numbers of peritumoral mast
cells (p = 0.006), peritumoral macrophages (p = 0.01), T
cells (CD3, intratumoral p = 0.007 and peritumoral p =
0.02) and cytotoxic T cells (CD8, peritumoral: p = 0.003,
intratumoral: p < 0.05).
Local recurrence
Six cell types were significantly associated with local re-
currence (Table 5). The presence of high numbers of in-
tratumoral NK cells, macrophages and T cells (CD4)
decreased the chance of local recurrence. Peritumoral
presence of high numbers of mast cells, eosinophils, and
neutrophils was also important in the univariate analy-
sis. Cox regression analysis (table 6) selected only peritu-
moral mast cells as marginally significant related to local
recurrence. When we analyze the influence of TNM clas-
sification together with the presence of mast cells, both
parameters did have a marginal effect.
Distant recurrence
Four cell types were correlateed with the development of
distant metastases (table 5). Both the peritumoral and
the intratumoral presence of a high number of macro-
phages and T cells (CD3, as well as the CD8 subset) were
a prognostic good sign and had a decreased risk on dis-
tant metastases. Presence of many peritumoral eosi-
nophils and mast cells decreased the chance of distant
recurrence. Cox regression (table 6) selected both peritu-
moral mast cells and intratumoral T cells as being the
most important. The amount of intratumoral T cells has
independent prognostic value additional to the TNM
classification, see also figure 2.
Survival analysis
In predicting survival, intratumoral macrophages, T cells
(CD3 and CD8), mast cells and peritumoral mast cells
and eosinophils are significant (table 5). Cox regression
(table 6) showed that peritumoral eosinophils and mast
cells are important for survival. The amount of peritu-
moral eosinophils has independent prognostic value ad-
ditional to the TNM classification.
Tumor characteristics
The amount of peritumoral T helper cells (CD4) and
eosinophils was correlated with the depth of tumor inva-
sion (p = 0.01 and p = 0.02), as well as with the amount
of intratumoral T cells (CD3, p = 0.04). Other cell types
did not have an association with depth of tumor inva-
sion. There was a clear relation with the lymph node sta-
tus (positive/negative) and the amount of peritumoral
eosinophils (p = 0.02), mast cells (p < 0.001), macro-
phages (intratumoral p = O.OS, peritumoral p = 0.004)
and T cells (intratumoral, p = 0.02). The presence of dis-
tant metastases at the time of surgery was not associated
Figure 1
Mutual relations between the inflammatory cell types regard-
less of location. Relations depicted by bold arrows show a
significant relationship with r ≥  0.25. T-cells (CD3, not
shown) show significant relations with all cell types (most
strongly to CD4 and macrophages r ≥  0.25).
Figure 2
Kaplan-Meier survival curves for the development of distant
recurrence showing the TNM independent effect of the
three categories of intratumoral T cells (CD3), p = 0.0004BMC Cancer (2001) 1:7 http://www.biomedcentral.com/1471-2407/1/7
with any cell type. Mucinous carcinomas showed less
peritumoral neutrophil, macrophage and T cell infiltrate.
There was no association of any cell type with the differ-
entiation grades, except for the presence of CD4 positive
cells (p = 0.02).
The numbers of peritumoral eosinophils, and infra- and
peritumoral macrophages and mast cells were related to
the stages in the TNM classification.
Table 5: Results of univariate log rank analyses for the risk on local recurrence, the risk on distant metastases and the survival.
local recurrence % distant metastases % cumulative survival %















intratumoral 18 26 34 0.45 30 54 56 0.08 72 67 62 0.94
peritumoral 42 24 14 0.007* 62 48 35 0.009* 56 65 83 0.0008*
neutrophils
intratumoral 35 23 23 0.42 46 49 47 0.85 61 68 73 0.66
peritumoral 44 - 22 0.02* 52 - 48 0.88 48 - 72 0.19
mast cells
intratumoral 42 23 20 0.17 65 47 39 0.08 45 74 71 0.006*
peritumoral 44 18 15 0.007* 86 38 21 <0.0001* 43 78 73 <0.0001*
macrophag-
es
intratumoral 41 25 9 0.03* 63 50 28 0.03* 56 70 75 0.006*
peritumoral 27 21 17 0.70 54 31 20 0.007* 70 68 67 0.50
NK cells
intratumoral 36 - 20 0.03* 50 - 47 0.58 57 - 73 0.15
peritumoral 27> - 23 0.65 52 - 40 0.22 68 - 68 0.87
T cells 
(CD3)
intratumoral 35 29 13 0.08 76 42 32 <0.0001* 57 67 75 0.002*
peritumoral 25 23 25 0.67 63 41 47 0.02* 60 70 69 0.17
CD4 T cells
intratumoral 33 31 10 0.01* 48 47 46 0.55 66 60 78 0.21
peritumoral 36 28 14 0.10 54 53 46 0.90 66 65 70 0.51
CD8 T cells
intratumoral 34 22 22 0.19 71 42 37 0.0005* 58 73 69 0.01*
peritumoral 27 - 20 0.11 58 - 19 0.002* 60 - 86 0.05
The marked cell types (*) show a significant correlation with prognosis. Median follow up is 35.4 months, n = 160BMC Cancer (2001) 1:7 http://www.biomedcentral.com/1471-2407/1/7
Discussion
The main purpose of this study was to evaluate the inter-
action between the specific and general inflammatory re-
action and the relation with prognosis of rectal cancer
patients. We showed that although a large specific anti-
tumor response reflected by T cells, protects against dis-
tant metastases, the effects on patient survival and local
recurrence are less important compared to the effects of
the nonspecific inflammatory response. The most impor-
tant representatives of the nonspecific inflammatory re-
sponse are mast cells, eosinophils and NK cells, less
important are the neutrophils and macrophages. In con-
trast to earlier studies [16,18] in which the presence of
mast cells has been described as a prognostic poor or in-
different factor, we found that the presence of many per-
itumoral mast cells is a prognostic good sign. An
explanation for these contradictionary results may be the
method of determination of mast cells. While in the pub-
lished studies the presence of mast cells was determined
by histochemical procedures, nowadays specific antibod-
ies are in use. This is confirmed by the finding of Nielsen
et al [17], who used the same tryptase antibody as we did
and also found a positive influence of many mast cells on
prognosis. Our data are in accordance with data obtained
in animal models. Mast cell deficient mice show an in-
creased tumor incidence compared to normal mice after
treatment with carcinogens. This increased tumor inci-
dence was not seen when the carcinogen was given after
bone marrow transplantation to overcome the mast cell
deficiency [25].
The peritumoral presence of mast cells is the most im-
portant prognostic factor for local recurrence in the uni-
variate analysis. The strong relation between the
presence of peritumoral mast cells and inflammatory in-
filtrate and the fact that in the multivariate analysis the
presence of inflammatory infiltrate is no longer signifi-
cant when compared to mast cell infiltrate, suggests that
this cell type is the most important cell type within this
infiltrate. This is not in contradiction with the original
definition of inflammatory or lymphoid or lymphocytic
infiltrate by Jass [26]: "stromal reaction in which lym-
phocytes are present as a part of a mixed chronic infil-
trate and not necessarily in large numbers".
However, within the inflammatory infiltrate other cell
types are important as well, like eosinophils and NK
cells. The close interactions of mast cells and eosinophils
are firmly established [27,28], but there are also func-
tional relationships between mast cells and T cells [29],
eosinophils and T cells [30], mast cells and macrophages
[5].
In the multivariate analysis for the development of dis-
tant metastases both the specific immune response (T
cells) and the nonspecific response (mast cells) demon-
strated prognostic value. Comparing this with the TNM
classification, the presence of T cells had independent
prognostic value additional to this classification. It is not
surprising that the specific immune response, which is
reflected by the presence of T cells in the tumor, but in re-
ality is a systemic reaction against tumor cells, has influ-
ence on the development of distant metastases.
Surprisingly, the nonspecific response, represented by
the mast cells in the selection and in the whole trial pop-
ulation the eosinophilic granulocytes, are also able to in-
fluence the development of distant metastases.
On the basis of our data we propose a model for the host
response in rectal cancer, in which there is an interaction
between the specific and the nonspecific inflammatory
reaction (figure 3). In this model we assume that tumors
can evoke a host response in three different ways, altered
antigenicity, cytokine production and tissue damage. It
is likely that these different mechanisms are integrated.
The specific immune response is directed against and at-
tracted by the altered antigenicity of the tumor cells [8],
while the nonspecific response might be a reaction to the
tissue damage caused by tumor invasion. The presence of
neutrophilic granulocytes is indicative of this phenome-
non. Both the specific and the nonspecific immune re-
sponse can be evoked by cytokine production by the
tumor and its microenvironment [31,32,33].
These three mechanisms are responsible for the develop-
ment of the host response, which consists of a specific
Figure 3
Model of specific and nonspecific host response. The specific
immune response are the T cells, the nonspecific immune
response is formed by eosinophilic and neutrophilic granulo-
cytes, mast cells, macrophages and NK cells.BMC Cancer (2001) 1:7 http://www.biomedcentral.com/1471-2407/1/7
and a nonspecific immune reaction. Both reactions are
necessary for the establishment of the host response,
which is demonstrated by the close correlations of the
different cell types in our study as well as from literature
data.
Table 6: Results of Cox regression analysis for local recurrence, distant metastases and survival.
tested variables cell types cell types/ TNM /
inflamm. infiltrate
RR 95% CI RR 95% CI
local recurrence peritumoral mast cells
- none/few 3.7 1.1 -12.8 1.9 0.5-7.1
-moderate 1.3 0.4- 4.4 0.9 0.3-3.1




n = 148 TNM
33 events - I/I I - 1.0
-III/IV 2.4 0.9-6.1
distant peritumoral mast cells
metastases - none/few 4.5 1.6-12.2 2.5 1.2-5.8
- moderate 1.1 0.4-2.9 0.9 0.3-2.3
- many 1.0 1.0
intratumoral T cells (CD3)
- none/few 3.2 1.5-6.8 2.6 1.2-5.8
-moderate 2.0 0.9-4.1 1.8 0.8-3.8
- many 1.0 1.0
inflammatory infiltrate
- none/few - 1.0
- extensive 1.0 0.4-2.9
n = 159 TNM
65 events -I/II - 1.0
-III/IV 4.4 1.9-9.9
survival peritumoral eosinophils
- none/few 3.6 1.5-8.7 3.0 1.2-7.2
-moderate 2.8 1.2-6.6 2.1 0.9-5.1
- many 1.0 1.0
peritumoral mast cells
- none/few 2.9 1.2-6.8 1.4 0.6-3.4
-moderate 0.8 0.4-1.9 0.6 0.3-1.4
- many 1.0 1.0
inflammatory infiltrate
- none/few - 1.0
- extensive 1.0 0.4-2.5
n = 136 TNM
59 events - I/II - 1.0
- III/IV 2.9 1.4-6.2
Cell types are included in the multivariate analysis if their p-value was less than 0.05 in the univariate analysis (table 3). Cell types are reported here 
and included in the multivariate analysis with TNM classification and inflammatory infiltrate, if they were significant in the Cox' regression of the cell 
types forward step-wise applied.BMC Cancer (2001) 1:7 http://www.biomedcentral.com/1471-2407/1/7
The peritumoral presence of the nonspecific infiltrate is
mainly involved in local control of the tumor process, as
gathered from the clear relation between mast cells and
local recurrence, whereas the specific response is mainly
concerned with the occurrence of hematogenous metas-
tases. The nonspecific infiltrate is indirectly linked to the
prevention of distant metastases by the interactions with
the specific response, as well as by the improved local
control.
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